CVRx, Inc. announced preliminary unaudited financial results on January 13, 2025, for the fourth quarter and full year 2024. The company expects fourth-quarter revenue to be between $15.2 million and $15.3 million, representing a significant growth of 35% over the prior year period.
For the full year 2024, CVRx anticipates total revenue to be between $51.1 million and $51.2 million, reflecting a 30% increase compared to 2023. These preliminary figures indicate continued strong commercial momentum for the Barostim therapy.
Looking ahead, CVRx issued its initial fiscal year 2025 revenue guidance, projecting between $63.0 million and $65.0 million. This guidance represents an expected growth rate of 23% to 27% for the upcoming year, signaling confidence in the sustained adoption of its neuromodulation solution for heart failure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.